Korea Arlico Pharm Co.,Ltd. (260660.KQ)

5,060.00 -20.00 (-0.39%) At close: 03:30PM KST

Korea Arlico Pharm Co.,Ltd.

Alico Pharmaceutical Building
7-21 Baumoe-ro 27- gil Seocho-gu
Seoul
South Korea
82 2 585 0004
https://www.arlico.co.kr

Sector(s): 
Industry: 
Full-time employees: 

Description

Korea Arlico Pharm Co.,Ltd. engages in the researches and develops, produces, and sells medicines in South Korea. It offers ETC, OTC, medical device, and other products; and active ingredients. The company provides products in the areas of circulatory system, anti-platelet, dementia, muscle relaxants, diabetes, NSAIDS and analgesics, ointment/cream, respiratory system, gastrointestinal, metabolic disease, antihistamines, anti-virus, genitourinary, alopecia, psychoneurotic, CNS, anthelmintics, and hypnotic diseases. Korea Arlico Pharm Co.,Ltd. was founded in 1992 and is headquartered in Seoul, South Korea.

Corporate governance

Korea Arlico Pharm Co.,Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.